Entries by bps

[Bio Spectator] Which Korean Company Was Accepted into the ‘Orphan Drug Designation’ Program by US FDA This Year?

Three Korean bio companies were accepted into the Organ Drugs Designation (ODD) program by the US FDA this year: Bio-Pharm Solutions in March, Medpacto in June, and LegoChem Biosciences in July. As the number of companies accepted into the ODD is greatly increasing due to the recent deregulatory move of the Trump Administration, Korean […]

[Bio Spectator] Bio-Pharm Solutions: “We will succeeded in developing a new epilepsy drug, and now aim to become a CNS specialist.”

‘JBPOS0101’ obtains FDA Orphan Drug Designation (ODD) approval “Like Admiral Yi Sunsin won a victory with 12 ships against 500 enemy ships, we have succeeded in developing a new global drug through strategic and tactical planning.” We met with CEO Choi Yong-moon in the headquarters of Bio-Pharm Solutions at the Advanced Institute of Convergence […]

[Medical News] Five Innovative New Drug Projects Selected

The Korea Drug Development Fund is out to provide new support. The Korea Drug Development Fund (CEO Joo Sang-eon, KDDF), which began its takeoff toward turning Korea into a global new drug developing country, recently selected 5 new support projects. According to the KDDF on May 3, among the innovative projects it received last […]

IR/PR

The oral medication for infantile spasms (IS) is in phase 2 clinical trialsin Korea and the US, and the IV medication for status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer’s Disease, and is set to embark on clinical trials (phase 2)… by expanding […]

IR/PR

The oral medication for infantile spasms (IS) is in phase 2 clinical trialsin Korea and the US, and the IV medication for status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer’s Disease, and is set to embark on clinical trials (phase 2)… by expanding […]

Bio-Pharm Solutions

145, Gwanggyo-ro, Yeongtong-gu, Suwon,
Gyeonggi-do, 16229, Korea
6F, C Bldg, Advanced Institute of Convergence Technology

CONTACT

Tel: 82-31-888-9608
Fax: 82-31-888-9601

MORE

Careers: shkim@b-psol.com
Clinical Trials: hsshin@b-psol.com
Investor Inquiries: uklee@b-psol.com
BD Partnering: uklee@b-psol.com